Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...

STORY: Shares of Novo Nordisk tumbled 10% Monday morning after the drugmaker revealed weaker-than-expected data about its ...

StockNews.com upgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a strong-buy rating in a report released on Thursday. A number of other analysts have also recently ...

Novo Nordisk announced a new cash-pay option for its blockbuster weight-loss drug Wegovy, offering a monthly dose at $499 and home delivery. The move follows competitor Eli Lilly ...

Stifel Nicolaus cut shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a hold rating in a report issued ...

Roller-coaster healthcare stock Hims & Hers Health ( HIMS -1.34%), whose stock got devastated last week by worries that it ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Nvidia shares have been under pressure since late January, when the release of a lower cost artificial intelligence (AI) ...

March 5 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said ... Persil-owner Henkel gives soft growth guidance, as weak North America weighs 8:22 AM UTC · Updated ago category China's ...

president of Novo Nordisk's North America business, in a statement Wednesday. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services ...

European stocks look like newly good investments amid Trump's tariff war and US economic unpredictabilities. European defense stocks are particularly appealing.

Bank of America Securities analyst Sachin Jain maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK1,075.00. The company’s shares closed ...